MedPath

A study to assess the equivalence in efficacy of anesthesia using topical Proxymetacaine 0.5% drops versus sub-conjunctival Lignocaine 2% (without adrenaline) for subsequent Intravitreal Injections of Ranibizumab (Lucentis): A Randomized Clinical Trial. - IVT Lucentis Anaesthetic Trial

Conditions
Wet Age-related Macular Degeneration
Registration Number
EUCTR2010-022644-21-GB
Lead Sponsor
Plymouth Hospitals NHS Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

Participant is willing and able to give informed consent for participation in the study.
Male or Female, aged 50 years or above.
Patients receiving subsequent doses of Intra Vitreal Lucentis Injection with a primary diagnosis of wet age related macular degeneration

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Patients not consenting to be included in the study.
Patients on pain medication.
Patients undergoing other Intra Vitreal procedure.
Patients undergoing Intra Vitreal injection of Ranibizumab for the first time.
Patients allergic to any components of the drug used in the study

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath